MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
- PMID: 35914239
- PMCID: PMC9481712
- DOI: 10.1158/0008-5472.CAN-22-1329
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Abstract
Triple-negative breast cancer (TNBC) is persistently refractory to therapy, and methods to improve targeting and evaluation of responses to therapy in this disease are needed. Here, we integrate quantitative MRI data with biologically based mathematical modeling to accurately predict the response of TNBC to neoadjuvant systemic therapy (NAST) on an individual basis. Specifically, 56 patients with TNBC enrolled in the ARTEMIS trial (NCT02276443) underwent standard-of-care doxorubicin/cyclophosphamide (A/C) and then paclitaxel for NAST, where dynamic contrast-enhanced MRI and diffusion-weighted MRI were acquired before treatment and after two and four cycles of A/C. A biologically based model was established to characterize tumor cell movement, proliferation, and treatment-induced cell death. Two evaluation frameworks were investigated using: (i) images acquired before and after two cycles of A/C for calibration and predicting tumor status after A/C, and (ii) images acquired before, after two cycles, and after four cycles of A/C for calibration and predicting response following NAST. For Framework 1, the concordance correlation coefficients between the predicted and measured patient-specific, post-A/C changes in tumor cellularity and volume were 0.95 and 0.94, respectively. For Framework 2, the biologically based model achieved an area under the receiver operator characteristic curve of 0.89 (sensitivity/specificity = 0.72/0.95) for differentiating pathological complete response (pCR) from non-pCR, which is statistically superior (P < 0.05) to the value of 0.78 (sensitivity/specificity = 0.72/0.79) achieved by tumor volume measured after four cycles of A/C. Overall, this model successfully captured patient-specific, spatiotemporal dynamics of TNBC response to NAST, providing highly accurate predictions of NAST response.
Significance: Integrating MRI data with biologically based mathematical modeling successfully predicts breast cancer response to chemotherapy, suggesting digital twins could facilitate a paradigm shift from simply assessing response to predicting and optimizing therapeutic efficacy.
©2022 American Association for Cancer Research.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9481712/bin/nihms-1828580-f0001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9481712/bin/nihms-1828580-f0002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9481712/bin/nihms-1828580-f0003.gif)
![Figure 4.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9481712/bin/nihms-1828580-f0004.gif)
![Figure 5.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/9481712/bin/nihms-1828580-f0005.gif)
Similar articles
-
Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis.Breast Cancer Res Treat. 2022 Dec;196(3):441-451. doi: 10.1007/s10549-022-06751-9. Epub 2022 Oct 8. Breast Cancer Res Treat. 2022. PMID: 36207620 Review.
-
Quantitative Apparent Diffusion Coefficients From Peritumoral Regions as Early Predictors of Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer.J Magn Reson Imaging. 2022 Dec;56(6):1901-1909. doi: 10.1002/jmri.28219. Epub 2022 May 2. J Magn Reson Imaging. 2022. PMID: 35499264 Free PMC article.
-
Early ultrasound evaluation identifies excellent responders to neoadjuvant systemic therapy among patients with triple-negative breast cancer.Cancer. 2021 Aug 15;127(16):2880-2887. doi: 10.1002/cncr.33604. Epub 2021 Apr 20. Cancer. 2021. PMID: 33878210 Free PMC article. Clinical Trial.
-
Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer.J Magn Reson Imaging. 2021 Jul;54(1):251-260. doi: 10.1002/jmri.27557. Epub 2021 Feb 15. J Magn Reson Imaging. 2021. PMID: 33586845
-
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC).Breast Cancer Res Treat. 2021 Jan;185(1):1-12. doi: 10.1007/s10549-020-05917-7. Epub 2020 Sep 13. Breast Cancer Res Treat. 2021. PMID: 32920733 Free PMC article. Review.
Cited by
-
Structural and practical identifiability of contrast transport models for DCE-MRI.PLoS Comput Biol. 2024 May 15;20(5):e1012106. doi: 10.1371/journal.pcbi.1012106. eCollection 2024 May. PLoS Comput Biol. 2024. PMID: 38748755 Free PMC article.
-
Digital twins for health: a scoping review.NPJ Digit Med. 2024 Mar 22;7(1):77. doi: 10.1038/s41746-024-01073-0. NPJ Digit Med. 2024. PMID: 38519626 Free PMC article. Review.
-
Toward mechanistic medical digital twins: some use cases in immunology.Front Digit Health. 2024 Mar 7;6:1349595. doi: 10.3389/fdgth.2024.1349595. eCollection 2024. Front Digit Health. 2024. PMID: 38515550 Free PMC article. Review.
-
A Pilot Study on Patient-specific Computational Forecasting of Prostate Cancer Growth during Active Surveillance Using an Imaging-informed Biomechanistic Model.Cancer Res Commun. 2024 Mar 1;4(3):617-633. doi: 10.1158/2767-9764.CRC-23-0449. Cancer Res Commun. 2024. PMID: 38426815 Free PMC article.
-
A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin.Cancer Biol Ther. 2024 Dec 31;25(1):2321769. doi: 10.1080/15384047.2024.2321769. Epub 2024 Feb 27. Cancer Biol Ther. 2024. PMID: 38411436 Free PMC article.
References
-
- Liu SV, Melstrom L, Yao K, Russell CA, Sener SF. Neoadjuvant therapy for breast cancer. J Surg Oncol 2010;101:283–291. - PubMed
-
- Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 2008;26:1275–1281. - PubMed
-
- Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med 2018;379(22):2108–2121. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical